In another liver disease, MASLD, overexpression of hepatic ActA was found to counteract MASLD by reducing liver steatosis, systemic fat accumulation, and inflammation, while improving insulin sensitivity (Liu, H. et al., 2023b). The gene discussed is ACTA1; the disease is liver disorder.